The US Food and Drug Administration has accepted and granted Priority Review for Bristol Myers Squibb (NYSE: BMY) and bluebird bio’s (Nasdaq: BLUE) Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121).
The drug candidate is the companies’ anti-BCMA chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.
Bluebird bio’s shares were up 2.9% at $56.07 in pre-market trading, while BMS was barely moved, rising just 0.5%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze